ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ABSK091 Sensitive: C3 – Early Trials
Nat Commun - 2 weeks (New C3)
|
ABSK091 Sensitive: C3 – Early Trials
Nat Commun - 2 weeks - (New C3)
|
RB1 deletion
|
Estrogen Receptor Positive Breast Cancer
|
RB1 deletion
|
Estrogen Receptor Positive Breast Cancer
|
IGM-9427 Sensitive: D – Preclinical
Oncogene - 2 weeks (New D)
|
IGM-9427 Sensitive: D – Preclinical
Oncogene - 2 weeks - (New D)
|
RB1 deletion
|
Estrogen Receptor Positive Breast Cancer
|
RB1 deletion
|
Estrogen Receptor Positive Breast Cancer
|
WEE1 inhibitor + Aurora kinase inhibitor Sensitive: D – Preclinical
Oncogene - 2 weeks (New D)
|
WEE1 inhibitor + Aurora kinase inhibitor Sensitive: D – Preclinical
Oncogene - 2 weeks - (New D)
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Trazimera (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ontruzant (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Ogivri (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Kanjinti (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
Herzuma (trastuzumab biosimilar) Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
ribociclib Sensitive: A1 - Approval
|
ribociclib Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
lapatinib Sensitive: A1 - Approval
|
lapatinib Sensitive: A1 - Approval
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
fulvestrant Sensitive: A1 - Approval
|
fulvestrant Sensitive: A1 - Approval
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 overexpression
|
Hormone Receptor Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
HER-2 amplification
|
Hormone Receptor Positive Breast Cancer
|
neratinib Sensitive: A1 - Approval
|
neratinib Sensitive: A1 - Approval
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
exemestane Sensitive: A1 - Approval
|
exemestane Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
letrozole Sensitive: A1 - Approval
|
letrozole Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
anastrozole Sensitive: A1 - Approval
|
anastrozole Sensitive: A1 - Approval
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
toremifene Sensitive: A1 - Approval
|
toremifene Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
talazoparib Sensitive: A1 - Approval
|
talazoparib Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
fulvestrant Sensitive: A1 - Approval
|
fulvestrant Sensitive: A1 - Approval
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
palbociclib Resistant: A2 - Guideline
|
palbociclib Resistant: A2 - Guideline
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
everolimus Sensitive: A2 - Guideline
|
everolimus Sensitive: A2 - Guideline
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
Aromatase inhibitor + palbociclib Sensitive: A2 - Guideline
|
Aromatase inhibitor + palbociclib Sensitive: A2 - Guideline
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
Aromatase inhibitor Sensitive: A2 - Guideline
|
Aromatase inhibitor Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Hormone Receptor Positive Breast Cancer
|
BRCA2 mutation
|
Hormone Receptor Positive Breast Cancer
|
PARP inhibitor Sensitive: A2 - Guideline
|
PARP inhibitor Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Hormone Receptor Positive Breast Cancer
|
BRCA1 mutation
|
Hormone Receptor Positive Breast Cancer
|
PARP inhibitor Sensitive: A2 - Guideline
|
PARP inhibitor Sensitive: A2 - Guideline
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
CDK6 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline
|
CDK6 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
CDK4 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline
|
CDK4 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
trastuzumab + lapatinib Resistant: B - Late Trials
|
trastuzumab + lapatinib Resistant: B - Late Trials
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
trastuzumab Resistant: B - Late Trials
|
trastuzumab Resistant: B - Late Trials
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
lapatinib Resistant: B - Late Trials
|
lapatinib Resistant: B - Late Trials
|
CCNE1 overexpression
|
Hormone Receptor Positive Breast Cancer
|
CCNE1 overexpression
|
Hormone Receptor Positive Breast Cancer
|
palbociclib Resistant: B - Late Trials
|
palbociclib Resistant: B - Late Trials
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
palbociclib Sensitive: B - Late Trials
|
palbociclib Sensitive: B - Late Trials
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
tamoxifen Sensitive: B - Late Trials
|
tamoxifen Sensitive: B - Late Trials
|
PLK1-H
|
Hormone Receptor Positive Breast Cancer
|
PLK1-H
|
Hormone Receptor Positive Breast Cancer
|
palbociclib Resistant: B - Late Trials
|
palbociclib Resistant: B - Late Trials
|
TP53 mutation
|
Hormone Receptor Positive Breast Cancer
|
TP53 mutation
|
Hormone Receptor Positive Breast Cancer
|
capecitabine Resistant: B - Late Trials
|
capecitabine Resistant: B - Late Trials
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
capecitabine Sensitive: B - Late Trials
|
capecitabine Sensitive: B - Late Trials
|
BRCA1 mutation
|
Hormone Receptor Positive Breast Cancer
|
BRCA1 mutation
|
Hormone Receptor Positive Breast Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
palbociclib + abemaciclib Sensitive: B - Late Trials
|
palbociclib + abemaciclib Sensitive: B - Late Trials
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
alpelisib Sensitive: B - Late Trials
|
alpelisib Sensitive: B - Late Trials
|
BRCA2 mutation
|
Hormone Receptor Positive Breast Cancer
|
BRCA2 mutation
|
Hormone Receptor Positive Breast Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
ER mutation
|
Hormone Receptor Positive Breast Cancer
|
ER mutation
|
Hormone Receptor Positive Breast Cancer
|
exemestane Resistant: B - Late Trials
|
exemestane Resistant: B - Late Trials
|
HER-2 underexpression
|
Hormone Receptor Positive Breast Cancer
|
HER-2 underexpression
|
Hormone Receptor Positive Breast Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials
|
fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
palbociclib Sensitive: B - Late Trials
|
palbociclib Sensitive: B - Late Trials
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
fulvestrant Sensitive: B - Late Trials
|
fulvestrant Sensitive: B - Late Trials
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
ER mutation
|
Estrogen Receptor Positive Breast Cancer
|
exemestane Resistant: B - Late Trials
|
exemestane Resistant: B - Late Trials
|
FGFR1 amplification
|
Hormone Receptor Positive Breast Cancer
|
FGFR1 amplification
|
Hormone Receptor Positive Breast Cancer
|
letrozole Resistant: B - Late Trials
|
letrozole Resistant: B - Late Trials
|
ER rs2234693
|
Hormone Receptor Positive Breast Cancer
|
ER rs2234693
|
Hormone Receptor Positive Breast Cancer
|
exemestane Sensitive: B - Late Trials
|
exemestane Sensitive: B - Late Trials
|
HSD17B2 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
HSD17B2 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
tamoxifen Sensitive: B - Late Trials
|
tamoxifen Sensitive: B - Late Trials
|
ER mutation
|
Hormone Receptor Positive Breast Cancer
|
ER mutation
|
Hormone Receptor Positive Breast Cancer
|
fulvestrant Sensitive: B - Late Trials
|
fulvestrant Sensitive: B - Late Trials
|
HR positive + HER-2 positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive + HER-2 positive
|
Hormone Receptor Positive Breast Cancer
|
Aromatase inhibitor + trastuzumab + lapatinib Sensitive: B - Late Trials
|
Aromatase inhibitor + trastuzumab + lapatinib Sensitive: B - Late Trials
|
BRCA1 mutation
|
Hormone Receptor Positive Breast Cancer
|
BRCA1 mutation
|
Hormone Receptor Positive Breast Cancer
|
talazoparib Sensitive: B - Late Trials
|
talazoparib Sensitive: B - Late Trials
|
BRCA2 mutation
|
Hormone Receptor Positive Breast Cancer
|
BRCA2 mutation
|
Hormone Receptor Positive Breast Cancer
|
talazoparib Sensitive: B - Late Trials
|
talazoparib Sensitive: B - Late Trials
|
IGFBP7 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
IGFBP7 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
tamoxifen Sensitive: B - Late Trials
|
tamoxifen Sensitive: B - Late Trials
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
RAD1901 Sensitive: B - Late Trials
|
RAD1901 Sensitive: B - Late Trials
|
ESR1 mutation
|
Estrogen Receptor Positive Breast Cancer
|
ESR1 mutation
|
Estrogen Receptor Positive Breast Cancer
|
palbociclib Sensitive: B - Late Trials
|
palbociclib Sensitive: B - Late Trials
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
denosumab Sensitive: B - Late Trials
|
denosumab Sensitive: B - Late Trials
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
abemaciclib Sensitive: C1 - Off-label
|
abemaciclib Sensitive: C1 - Off-label
|
PIK3CA mutation + HR positive
|
Hormone Receptor Positive Breast Cancer
|
PIK3CA mutation + HR positive
|
Hormone Receptor Positive Breast Cancer
|
alpelisib Sensitive: C1 - Off-label
|
alpelisib Sensitive: C1 - Off-label
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria
|
Z-endoxifen hydrochloride Sensitive: C2 – Inclusion Criteria
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria
|
trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
SAR439859 Sensitive: C2 – Inclusion Criteria
|
SAR439859 Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
Hormone Receptor Positive Breast Cancer
|
HER-2 mutation
|
Hormone Receptor Positive Breast Cancer
|
trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria
|
trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
enzalutamide capsule Sensitive: C2 – Inclusion Criteria
|
enzalutamide capsule Sensitive: C2 – Inclusion Criteria
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
abemaciclib Sensitive: C2 – Inclusion Criteria
|
abemaciclib Sensitive: C2 – Inclusion Criteria
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ribociclib Sensitive: C2 – Inclusion Criteria
|
ribociclib Sensitive: C2 – Inclusion Criteria
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
HR positive
|
Hormone Receptor Positive Breast Cancer
|
ST101 Sensitive: C2 – Inclusion Criteria
|
ST101 Sensitive: C2 – Inclusion Criteria
|
PIK3CA mutation
|
Hormone Receptor Positive Breast Cancer
|
PIK3CA mutation
|
Hormone Receptor Positive Breast Cancer
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
alpelisib Sensitive: C2 – Inclusion Criteria
|
PTEN mutation
|
Estrogen Receptor Positive Breast Cancer
|
PTEN mutation
|
Estrogen Receptor Positive Breast Cancer
|
AZD5363 Sensitive: C2 – Inclusion Criteria
|
AZD5363 Sensitive: C2 – Inclusion Criteria
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
tamoxifen Sensitive: C2 – Inclusion Criteria
|
tamoxifen Sensitive: C2 – Inclusion Criteria
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
anastrozole Sensitive: C2 – Inclusion Criteria
|
anastrozole Sensitive: C2 – Inclusion Criteria
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
letrozole Sensitive: C2 – Inclusion Criteria
|
letrozole Sensitive: C2 – Inclusion Criteria
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
RG4733 Sensitive: C2 – Inclusion Criteria
|
RG4733 Sensitive: C2 – Inclusion Criteria
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
SNDX-275 Sensitive: C2 – Inclusion Criteria
|
SNDX-275 Sensitive: C2 – Inclusion Criteria
|
EPRS1 expression
|
Estrogen Receptor Positive Breast Cancer
|
EPRS1 expression
|
Estrogen Receptor Positive Breast Cancer
|
tamoxifen Sensitive: C3 – Early Trials
|
tamoxifen Sensitive: C3 – Early Trials
|
FTO expression
|
Estrogen Receptor Positive Breast Cancer
|
FTO expression
|
Estrogen Receptor Positive Breast Cancer
|
tamoxifen Sensitive: C3 – Early Trials
|
tamoxifen Sensitive: C3 – Early Trials
|
CTDSP1 expression
|
Estrogen Receptor Positive Breast Cancer
|
CTDSP1 expression
|
Estrogen Receptor Positive Breast Cancer
|
tamoxifen Sensitive: C3 – Early Trials
|
tamoxifen Sensitive: C3 – Early Trials
|
BIN3 expression
|
Estrogen Receptor Positive Breast Cancer
|
BIN3 expression
|
Estrogen Receptor Positive Breast Cancer
|
tamoxifen Sensitive: C3 – Early Trials
|
tamoxifen Sensitive: C3 – Early Trials
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
ER positive
|
Estrogen Receptor Positive Breast Cancer
|
bevacizumab Sensitive: C3 – Early Trials
|
bevacizumab Sensitive: C3 – Early Trials
|
ER Y537S
|
Estrogen Receptor Positive Breast Cancer
|
ER Y537S
|
Estrogen Receptor Positive Breast Cancer
|
fulvestrant Sensitive: C3 – Early Trials
|
fulvestrant Sensitive: C3 – Early Trials
|
PIK3R1 mutation
|
Hormone Receptor Positive Breast Cancer
|
PIK3R1 mutation
|
Hormone Receptor Positive Breast Cancer
|
lenvatinib Resistant: C3 – Early Trials
|
lenvatinib Resistant: C3 – Early Trials
|
CDK6 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
CDK6 overexpression
|
Estrogen Receptor Positive Breast Cancer
|
fulvestrant Resistant: C3 – Early Trials
|
fulvestrant Resistant: C3 – Early Trials
|
RSF1 amplification
|
Estrogen Receptor Positive Breast Cancer
|
RSF1 amplification
|
Estrogen Receptor Positive Breast Cancer
|
tamoxifen Resistant: C3 – Early Trials
|
tamoxifen Resistant: C3 – Early Trials
|
AURKA overexpression
|
Estrogen Receptor Positive Breast Cancer
|
AURKA overexpression
|
Estrogen Receptor Positive Breast Cancer
|
tamoxifen Resistant: C3 – Early Trials
|
tamoxifen Resistant: C3 – Early Trials
|
USH2A mutation
|
Hormone Receptor Positive Breast Cancer
|
USH2A mutation
|
Hormone Receptor Positive Breast Cancer
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
NEFH mutation
|
Hormone Receptor Positive Breast Cancer
|
NEFH mutation
|
Hormone Receptor Positive Breast Cancer
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
APC mutation
|
Hormone Receptor Positive Breast Cancer
|
APC mutation
|
Hormone Receptor Positive Breast Cancer
|
lenvatinib Resistant: C3 – Early Trials
|
lenvatinib Resistant: C3 – Early Trials
|
PTCH1 mutation
|
Hormone Receptor Positive Breast Cancer
|
PTCH1 mutation
|
Hormone Receptor Positive Breast Cancer
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
PALB2 mutation
|
Hormone Receptor Positive Breast Cancer
|
PALB2 mutation
|
Hormone Receptor Positive Breast Cancer
|
lenvatinib Resistant: C3 – Early Trials
|
lenvatinib Resistant: C3 – Early Trials
|